All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.
Introducing
Now you can personalise
your Multiple Myeloma Hub experience!
Bookmark content to read later
Select your specific areas of interest
View content recommended for you
Find out moreThe Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Multiple Myeloma Hub is an independent medical education platform, sponsored by Bristol Myers Squibb, GSK, Pfizer, Roche and Sanofi. The levels of sponsorship listed are reflective of the amount of funding given. Digital educational resources delivered on the Multiple Myeloma Hub are supported by an educational grant from Janssen Biotech, Inc. View funders.
Bookmark this article
Multiple Myeloma Hub Symposium 2024: How to sequence BCMA-directed therapies in early RRMM
Test your knowledge! Take our quick quiz before and after you read this article to find out if you improved your knowledge. Results help us to improve content and continually provide open-access education.
At the ESH 7th Translational Research Conference on Multiple Myeloma in 2024, the Multiple Myeloma Hub held a symposium titled: How to sequence B-cell maturation antigen (BCMA)-directed therapies in early relapsed/refractory multiple myeloma (RRMM). During the symposium, Rakesh Popat, UCL Hospitals NHS Foundation Trust, London, UK, delivered an expert presentation on the existing and developing treatment paradigm for early RRMM.
In this presentation, Popat discusses the evolving treatment paradigm for early RRMM, highlighting emerging therapeutic approaches, the expansion of existing therapies into earlier treatment lines, and the latest clinical trial data. Popat emphasizes the importance of tailoring treatments based on patient-specific factors, such as genetic risk, transplant eligibility, and frailty (Figure 1), while considering the place for immunotherapies with different targets (Figure 2) in the early relapse setting. Popat discusses promising data associated with the use of BCMA-targeted therapies in earlier lines, as well as the challenges of sequencing these therapies across different patient populations and access issues globally.
Figure 1. Factors involved in choosing treatment regimens for RRMM*
AE, adverse event; ASCT, autologous stem cell transplant; BM, bone marrow; PC, plasma cells; PCL, plasma cell leukemia; RRMM, relapsed/refractory multiple myeloma.
*Devarakonda et al.1
Figure 2. Targets for immunotherapies in multiple myeloma*
ADC, antibody–drug conjugate; BCMA, B-cell maturation antigen; bsAb, bispecific antibody; cilta-cel, ciltacabtagene autoleucel; FcRH5, Fc receptor homolog 5; GPRC5D, G protein-coupled receptor class C group 5 member D; ide-cel, idecabtagene vicleucel.
*Parrondo et al.2
This independent educational activity is supported by GSK. All content was developed independently by the faculty. The funder was allowed no influence on the content of this activity.
Multiple Myeloma Hub Symposium 2024: How to sequence BCMA-directed therapies in early RRMM
Your opinion matters
Subscribe to get the best content related to multiple myeloma delivered to your inbox